<div class="p4l_caption"><div class="p4l_captionTitle"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4168072/" ref="ordinalpos=2780&amp;ncbi_uid=6648708&amp;link_uid=PMC4168072" image-link="/pmc/articles/PMC4168072/figure/F2/" class="imagepopup">Figure 2.  From: Smad3 phospho-isoform <span class="highlight" style="background-color:">signaling</span> in hepatitis C virus-related chronic liver diseases. </a></div><br /><div class="p4l_captionBody">Smad3 phospho-isoform signaling: Tumor suppressive TβRI/pSmad3C pathway vs carcinogenic JNK/pSmad3L pathway. A: In normal hepatocytes, transforming growth factor (TGF)-β activates the TGF-β type I receptor (TβRI), leading to the direct phosphorylation of the C-terminal region of Smad3. The C-terminal phosphorylated Smad3 (pSmad3C) moves to the nucleus and transmits cytostatic signals by up-regulating p21WAF1. The TβRI/pSmad3C pathway is crucial for homeostasis and is a tumor suppressor; B: In hepatocytes affected by mitogenic stimuli, pro-inflammatory cytokines activate c-Jun N-terminal kinase (JNK), drastically altering the Smad3 signaling to induce the phosphorylation of Smad3 at its linker region. The linker-phosphorylated Smad3 (pSmad3L) undergoes translocation to the nucleus to stimulate c-Myc transcription, resulting in a proliferative state. During hepatitis C virus-related chronic liver disease progression, the JNK/pSmad3L pathway is constitutively activated and promotes carcinogenesis.</div></div>